Dishman Carbogen Amcis growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+8.1%+3.7%+8.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+20.6%+63.7%−13.8%
+29.5%+819.2%−147.3%
+2,907.7%+102.1%−414.9%
+2,861.9%+102.1%−415.3%
+19.2%+4.4%+1.4%
+14.5%+3.6%−3.1%
+31.0%−2.3%+74.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹136.00

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,132 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+8.4+3.7+8.1—
EBITDA Growth—-13.8+63.7+20.6—
EBIT Growth—-147.3+819.2+29.5—
Net Income Growth—-414.9+102.1+2,907.7—
EPS Growth—-415.3+102.1+2,861.9—
Total Assets Growth—+1.4+4.4+19.2—
Total Equity Growth—-3.1+3.6+14.5—
Cash from Operations Growth—+74.3-2.3+31.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.